Business Description
Aridis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0403341045
Description
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.01 | |||||
| Equity-to-Asset | -1.81 | |||||
| Debt-to-Equity | -0.41 | |||||
| Debt-to-EBITDA | -8.43 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -40.73 | |||||
| Beneish M-Score | 68.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.7 | |||||
| 3-Year EPS without NRI Growth Rate | 22.7 | |||||
| 3-Year FCF Growth Rate | -16.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.43 | |||||
| 9-Day RSI | 44.08 | |||||
| 14-Day RSI | 44.13 | |||||
| 6-1 Month Momentum % | -8.52 | |||||
| 12-1 Month Momentum % | -61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | |||||
| Quick Ratio | 0.24 | |||||
| Days Sales Outstanding | 10.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.7 | |||||
| Shareholder Yield % | 83.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4.49 | |||||
| Net Margin % | -5.81 | |||||
| FCF Margin % | -91.28 | |||||
| ROA % | -11.59 | |||||
| ROIC % | -4.37 | |||||
| ROC (Joel Greenblatt) % | -44.41 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.11 | |||||
| EV-to-EBIT | -8.72 | |||||
| EV-to-EBITDA | -13.42 | |||||
| EV-to-Revenue | 0.39 | |||||
| EV-to-Forward-Revenue | 1.05 | |||||
| EV-to-FCF | -0.43 | |||||
| Earnings Yield (Greenblatt) % | -11.47 | |||||
| FCF Yield % | -633.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ARDS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aridis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 19.647 | ||
| EPS (TTM) ($) | -0.162 | ||
| Beta | 1.49 | ||
| Volatility % | 151.72 | ||
| 14-Day RSI | 44.13 | ||
| 14-Day ATR ($) | 0.007271 | ||
| 20-Day SMA ($) | 0.068523 | ||
| 12-1 Month Momentum % | -61 | ||
| 52-Week Range ($) | 0.05 - 0.5395 | ||
| Shares Outstanding (Mil) | 44.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aridis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aridis Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aridis Pharmaceuticals Inc Frequently Asked Questions
What is Aridis Pharmaceuticals Inc(ARDS)'s stock price today?
The current price of ARDS is $0.06. The 52 week high of ARDS is $0.54 and 52 week low is $0.05.
When is next earnings date of Aridis Pharmaceuticals Inc(ARDS)?
The next earnings date of Aridis Pharmaceuticals Inc(ARDS) is 2024-06-07 Est..
Does Aridis Pharmaceuticals Inc(ARDS) pay dividends? If so, how much?
Aridis Pharmaceuticals Inc(ARDS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers